Pleural
Deep learning with deep convolutional neural network using FDG-PET/CT for malignant pleural mesothelioma diagnosis
Oncotarget 2021 June 18 [Link] Kazuhiro Kitajima, Hidetoshi Matsuo, Atsushi Kono, Kozo Kuribayashi, Takashi Kijima, Masaki Hashimoto, Seiki Hasegawa, Takamichi Murakami, Koichiro Yamakado Abstract Objectives: This study analyzed an artificial intelligence (AI) deep learning method with a three-dimensional deep convolutional neural network (3D DCNN) in regard to diagnostic accuracy to differentiate malignant pleural mesothelioma (MPM)…
Read MoreThe association between pleural fluid exposure and survival in pleural mesothelioma
Chest 2021 June 10 [Link] Rachelle Asciak, Nikolaos I Kanellakis, Anna Bibby, Andrew Kidd, Stephen Gerry, Rachel Mercer, Nick Maskell, Kevin G Blyth, Peter Fsadni, Stephen Montefort, Ioannis Psallidas, Najib M Rahman Abstract Background: Most patients with malignant pleural mesothelioma (MPM) present with malignant pleural effusion (MPE). There is in vitro evidence that MPE may…
Read MoreOxytocin receptor is a promising therapeutic target of malignant mesothelioma
Cancer Science 2021 June 11 [Link] Yuta Kodama, Ichidai Tanaka, Tatsuhiro Sato, Kazumi Hori, Soei Gen, Masahiro Morise, Daisuke Matsubara, Mitsuo Sato, Yoshitaka Sekido, Naozumi Hashimoto Abstract Malignant mesothelioma (MM) is one of the most aggressive tumors. We conducted bioinformatics analysis using Cancer Cell Line Encyclopedia (CCLE) datasets to identify new molecular markers in MM.…
Read MoreThe Impact of Adjuvant Hemithoracic Radiation on Outcomes in Patients with Stage I-III Malignant Pleural Mesothelioma: A Dual Registry Analysis
Annals of Surgery 2021 June 4 [Link] Vignesh Raman, Soraya L Voigt, Oliver K Jawitz, Norma E Farrow, Kristen E Rhodin, Chi-Fu Jeffrey Yang, Betty C Tong, Thomas A D’Amico, David H Harpole Abstract Background: The outcomes associated with receipt of adjuvant radiation in patients following surgery for malignant pleural mesothelioma (MPM) are poorly understood.…
Read MoreEssential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)
British Journal of Cancer 2021 June 4 [Link] Moshe Lapidot, Abigail E Case, Ellen L Weisberg, Chengcheng Meng, Sarah R Walker, Swati Garg 2 3, Wei Ni, Klaus Podar, Yin P Hung, Ruben D Carrasco, Aine Knott, Prafulla C Gokhale, Sunil Sharma, Alex Pozhitkov, Prakash Kulkarni, David A Frank, Ravi Salgia, James D Griffin, Srinivas…
Read MoreNew DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment
Cancers (Basel) 2021 May 27 [Link] Giovanni Cugliari, Alessandra Allione, Alessia Russo, Chiara Catalano, Elisabetta Casalone, Simonetta Guarrera, Federica Grosso, Daniela Ferrante, Marika Sculco, Marta La Vecchia, Chiara Pirazzini, Roberta Libener, Dario Mirabelli, Corrado Magnani, Irma Dianzani, Giuseppe Matullo Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasm. Patients are usually diagnosed when…
Read MoreSurgical Management and Reconstruction of Diaphragm, Pericardium and Chest Wall in Mesothelioma Surgery: A Review
Journal of Clinical Medicine 2021 May 26 [Link] Pietro Bertoglio, Elena Garelli, Jury Brandolini, Kenji Kawamukai, Filippo Antonacci, Sara Ricciardi, Alessandro Cipolli, Barbara Bonfanti, Sergio Nicola Forti Parri, Niccolò Daddi, Giampiero Dolci, Piergiorgio Solli Abstract Mesothelioma is an aggressive disease arising from parietal pleura. Surgery is a valuable option in the frame of a multimodality…
Read MorePathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma
Cancers 2021 May 24 [Link] Francesca Napoli, Angela Listì, Vanessa Zambelli, Gianluca Witel, Paolo Bironzo, Mauro Papotti, Marco Volante, Giorgio Scagliotti, Luisella Righi Abstract Malignant pleural mesothelioma (MPM) is a rare and highly aggressive disease that arises from pleural mesothelial cells, characterized by a median survival of approximately 13-15 months after diagnosis. The primary cause…
Read MoreNIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
Journal of Translational Medicine 2021 May 31 [Link] Vilde Drageset Haakensen, Anna K Nowak, Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Tine Mcculloch, Oscar Grundberg, Susana M Cedres, Åslaug Helland Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour. For patients with inoperable disease, few treatment options are…
Read MoreUpdate on Diagnosing and Reporting Malignant Pleural Mesothelioma
Acta Medica Academica 2021 April [Link] Ivana Savic, Jeffrey Myers Abstract In this review, we summarize current approaches to diagnosis of malignant pleural mesothelioma, focusing on the distinction from benign mesothelial proliferations and other malignant tumors. Current recommendations for reporting histological sub-type and tumor grade are also reviewed. Particular emphasis is placed on immunohistochemical and…
Read More